{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:24Z","timestamp":1753892124799,"version":"3.41.2"},"reference-count":7,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Calcitonin gene-related peptide (CGRP) pathway-targeted treatments have been shown to be efficacious in the prevention of episodic and chronic migraine. Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab) and the CGRP receptor (erenumab), and small molecule CGRP receptor antagonists (atogepant and rimegepant). While CGRP pathway\u2013targeted treatments are generally well-tolerated, in a review article by Holzer and Holzer-Petsche published in the January 2022 issue of <jats:italic>Frontiers in Physiology<\/jats:italic> the authors discussed the role of the CGRP pathway in gastrointestinal physiology, with a specific focus on constipation associated with the use of CGRP pathway\u2013targeted treatments. The authors state that real-world surveys have shown constipation to be a \u201cmajor adverse event\u201d reported in \u201cmore than 50% of patients treated with erenumab, fremanezumab or galcanezumab.\u201d As described in the current commentary, the limited data from the cited references in the review article by Holzer and Holzer-Petsche do not support that statement.<\/jats:p>","DOI":"10.3389\/fphys.2022.1067274","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:17:00Z","timestamp":1669709820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide\u2019s motor-stimulating and prosecretory function in the intestine"],"prefix":"10.3389","volume":"13","author":[{"given":"Kimberly D.","family":"Mackenzie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoel","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena Ramirez","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda J.","family":"Krasenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","article-title":"Safety and tolerability of 3 CGRP monoclonal antibodies in practice: A retrospective cohort study","volume":"60","author":"Alex","year":"2020","journal-title":"Headache"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","article-title":"Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study","volume":"28","author":"de Vries Lentsch","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cpt.1638","article-title":"Are novel, nonrandomized analytic methods fit for decision making? The need for prospective, controlled and transparent validation","volume":"107","author":"Eichler","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"82006","DOI":"10.3389\/fphys.2021.82006","article-title":"Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide\u2019s motor-stimulating and prosecretory function in the intestine","volume":"12","author":"Holzer","year":"2022","journal-title":"Front. Physiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/pm\/pnw255","article-title":"Opioid-induced constipation and bowel dysfunction: A clinical guideline","volume":"18","author":"M\u00fcller-Lissner","year":"2017","journal-title":"Pain Med."},{"key":"B6","first-page":"58","article-title":"CGRP monoclonal antibodies for chronic migraine: Year 1 of clinical use","volume":"19","author":"Robbins","year":"2019","journal-title":"Pract. Pain Manag."},{"key":"B7","first-page":"48","article-title":"CGRP monoclonal antibodies for chronic migraine prevention: Evaluation of adverse effects using a checklist","volume":"20","author":"Robbins","year":"2020","journal-title":"Pract. Pain Manag."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.1067274\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:17:02Z","timestamp":1669709822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.1067274\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":7,"alternative-id":["10.3389\/fphys.2022.1067274"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.1067274","relation":{},"ISSN":["1664-042X"],"issn-type":[{"type":"electronic","value":"1664-042X"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1067274"}}